Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure
AstraZeneca Drug DELIVERs At ESC
Treatment with Farxiga led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure, putting it in the same ballpark as Boehringer Ingelheim and Eli Lilly's Jardiance and its 21% reduction shown in the EMPEROR-Preserved trial last year.
